Skip header and navigation

Refine By

67 records – page 1 of 7.

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

https://arctichealth.org/en/permalink/ahliterature149701
Source
Lancet. 2009 Aug 22;374(9690):620-7
Publication Type
Article
Date
Aug-22-2009
Author
Jari Tiihonen
Jouko Lönnqvist
Kristian Wahlbeck
Timo Klaukka
Leo Niskanen
Antti Tanskanen
Jari Haukka
Author Affiliation
Department of Forensic Psychiatry, University of Kuopio and Niuvanniemi Hospital, Department of Clinical Physiology, Kuopio University Hospital, Kuopio, Finland. jari.tiihonen@niuva.fi
Source
Lancet. 2009 Aug 22;374(9690):620-7
Date
Aug-22-2009
Language
English
Publication Type
Article
Keywords
Adult
Age Distribution
Aged
Antipsychotic Agents - adverse effects
Case-Control Studies
Cause of Death
Clozapine - adverse effects
Dibenzothiazepines - adverse effects
Drug Utilization - trends
Female
Finland - epidemiology
Follow-Up Studies
Health Status Disparities
Humans
Life expectancy
Male
Middle Aged
Patient Readmission - statistics & numerical data
Perphenazine - adverse effects
Proportional Hazards Models
Registries
Risk factors
Schizophrenia - drug therapy - mortality
Sex Distribution
Time Factors
Abstract
The introduction of second-generation antipsychotic drugs during the 1990s is widely believed to have adversely affected mortality of patients with schizophrenia. Our aim was to establish the long-term contribution of antipsychotic drugs to mortality in such patients.
Nationwide registers in Finland were used to compare the cause-specific mortality in 66 881 patients versus the total population (5.2 million) between 1996, and 2006, and to link these data with the use of antipsychotic drugs. We measured the all-cause mortality of patients with schizophrenia in outpatient care during current and cumulative exposure to any antipsychotic drug versus no use of these drugs, and exposure to the six most frequently used antipsychotic drugs compared with perphenazine use.
Although the proportional use of second-generation antipsychotic drugs rose from 13% to 64% during follow-up, the gap in life expectancy between patients with schizophrenia and the general population did not widen between 1996 (25 years), and 2006 (22.5 years). Compared with current use of perphenazine, the highest risk for overall mortality was recorded for quetiapine (adjusted hazard ratio [HR] 1.41, 95% CI 1.09-1.82), and the lowest risk for clozapine (0.74, 0.60-0.91; p=0.0045 for the difference between clozapine vs perphenazine, and p
Notes
Comment In: Lancet. 2009 Nov 7;374(9701):1591; author reply 1592-319897117
Comment In: Lancet. 2009 Nov 7;374(9701):1591; author reply 1592-319897118
Comment In: Lancet. 2009 Aug 22;374(9690):590-219595448
Comment In: Lancet. 2009 Nov 7;374(9701):1592; author reply 1592-319897121
Comment In: Lancet. 2009 Nov 7;374(9701):1592; author reply 1592-319897120
PubMed ID
19595447 View in PubMed
Less detail

Adult schizotypal personality characteristics and prenatal influenza in a Finnish birth cohort.

https://arctichealth.org/en/permalink/ahliterature191446
Source
Schizophr Res. 2002 Mar 1;54(1-2):7-16
Publication Type
Article
Date
Mar-1-2002
Author
Ricardo A Machón
Matti O Huttunen
Sarnoff A Mednick
Juhani Sinivuo
Antti Tanskanen
Jennifer Bunn Watson
Markus Henriksson
Reijo Pyhälä
Author Affiliation
Department of Psychology, Loyola Marymount University, University Hall, One LMU Drive, Suite 4700, Los Angeles, CA 90045-2659, USA. RMACHON@LMU.EDU
Source
Schizophr Res. 2002 Mar 1;54(1-2):7-16
Date
Mar-1-2002
Language
English
Publication Type
Article
Keywords
Adult
Disease Outbreaks
Fetal Diseases - diagnosis - epidemiology
Finland - epidemiology
Humans
Incidence
Influenza, Human - diagnosis - epidemiology
MMPI
Male
Schizotypal Personality Disorder - diagnosis - epidemiology
Abstract
Recent evidence suggests that schizophrenia may result from a disruption of normal brain development during a critical, prenatal risk period in the 6th month of gestation. The phenotypic diagnostic manifestation of a basic genetic-neurodevelopmental disorder may consist of characteristics approximated by the DSM-IV diagnosis of "schizotypal personality disorder" (SPD). We identified male conscripts in Finland who, as fetuses, were exposed to the 1969 Hong Kong Influenza epidemic, along with a group of controls born during a relatively low year (1971) for infectious epidemics. It was hypothesized that among fetuses exposed to the influenza epidemic in their 6th month of gestation, we would observe an increased frequency of elevated (upper quartile) scores on a schizotypal personality characteristics (SPC) scale as compared to controls. A significantly higher proportion of the 6th month index exposed subjects (39%) had "elevated" SPC scale scores as compared to their controls (26%) (p
PubMed ID
11853973 View in PubMed
Less detail

Advanced paternal age and parental history of schizophrenia.

https://arctichealth.org/en/permalink/ahliterature131103
Source
Schizophr Res. 2011 Dec;133(1-3):125-32
Publication Type
Article
Date
Dec-2011
Author
Brian Miller
Jaana Suvisaari
Jouko Miettunen
Marjo-Riitta Järvelin
Jari Haukka
Antti Tanskanen
Jouko Lönnqvist
Matti Isohanni
Brian Kirkpatrick
Author Affiliation
Department of Psychiatry and Health Behavior, Medical College of Georgia Health Sciences University, Augusta, Georgia 30912, United States. brmiller@georgiahealth.edu
Source
Schizophr Res. 2011 Dec;133(1-3):125-32
Date
Dec-2011
Language
English
Publication Type
Article
Keywords
Adult
Age Factors
Aged
Cohort Studies
Family Health
Female
Finland
Humans
Logistic Models
Male
Maternal Age
Middle Aged
Odds Ratio
Paternal Age
Retrospective Studies
Risk factors
Schizophrenia - epidemiology - genetics
Young Adult
Abstract
Advanced paternal age (APA) is a risk factor for nonaffective psychosis (NAP) in the offspring, although the mechanism(s) of this association are not clear. The aim of this study was to examine whether later childbearing can be explained by parental schizophrenia, and in doing so, further evaluate the "de novo mutation" hypothesis for the association between APA and NAP.
Using binary logistic regression, the association between APA and parental history of schizophrenia in the offspring, considering maternal and paternal history separately, was examined in 1) all persons with NAP born in Finland between 1950 and 1969 (Finnish NAP Cohort, n = 13,712), and 2) members of the Northern Finland 1966 Birth Cohort (NFBC 1966, n = 10,224), a general population birth cohort.
In the Finnish NAP Cohort, having a mother with schizophrenia was associated with APA (Odds Ratio [OR] for linear trend = 1.20, 95% confidence interval 1.12-1.29, p
PubMed ID
21937198 View in PubMed
Less detail

Alexithymia and suicidal ideation: a 12-month follow-up study in a general population.

https://arctichealth.org/en/permalink/ahliterature178650
Source
Compr Psychiatry. 2004 Sep-Oct;45(5):340-5
Publication Type
Article
Author
Jukka Hintikka
Kirsi Honkalampi
Heli Koivumaa-Honkanen
Risto Antikainen
Antti Tanskanen
Kaisa Haatainen
Heimo Viinamäki
Author Affiliation
Department of Psychiatry, Kuopio University Hospital, Finland.
Source
Compr Psychiatry. 2004 Sep-Oct;45(5):340-5
Language
English
Publication Type
Article
Keywords
Adult
Affective Symptoms - diagnosis - epidemiology - psychology
Alcohol drinking - epidemiology
Depressive Disorder, Major - diagnosis - epidemiology - psychology
Female
Finland - epidemiology
Follow-Up Studies
Health status
Humans
Male
Middle Aged
Population Surveillance - methods
Prevalence
Questionnaires
Risk factors
Smoking - epidemiology
Socioeconomic Factors
Suicide, Attempted - statistics & numerical data
Unemployment - statistics & numerical data
Abstract
Alexithymic features are often associated with depression, which is the most important risk factor for suicidal behaviors. Nevertheless, little is known about the associations between alexithymia and suicidality. In this 12-month follow-up study we investigated the relationship between alexithymia and suicidal ideation in a sample of the general population (N = 1,563) using the 20-item Toronto Alexithymia Scale (TAS-20) and the 21-item Beck Depression Inventory (BDI). Suicidal ideation was more common among subjects with alexithymia than among nonalexithymic subjects (32% v 9% at baseline and 36% v 9% after 12 months). In cross-sectional analyses, alexithymia associated with the presence of suicidal ideation even after adjustment for sex, age, and several psychosocial and socioeconomic factors and the presence of depression. Moreover, after adjustment for depression at baseline, the decrease and increase in alexithymic features during the study period associated independently with recovery from and the occurrence of suicidal ideation, respectively. Nevertheless, these associations were no longer independent when adjusted for concomitant changes in the level of depressive symptoms. In conclusion, if depression presents alexithymic features the subject has an additive impact on the risk of suicidal ideation.
PubMed ID
15332196 View in PubMed
Less detail

Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.

https://arctichealth.org/en/permalink/ahliterature260126
Source
Int Clin Psychopharmacol. 2014 Jul;29(4):216-23
Publication Type
Article
Date
Jul-2014
Author
Heidi Taipale
Antti Tanskanen
Marjaana Koponen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Source
Int Clin Psychopharmacol. 2014 Jul;29(4):216-23
Date
Jul-2014
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy
Cholinesterase Inhibitors - adverse effects - therapeutic use
Cohort Studies
Diagnostic and Statistical Manual of Mental Disorders
Drug Monitoring
Drug Prescriptions
Drug Therapy, Combination - adverse effects
Excitatory Amino Acid Antagonists - adverse effects - therapeutic use
Female
Finland
Follow-Up Studies
Galantamine - adverse effects - therapeutic use
Guideline Adherence
Humans
Indans - adverse effects - therapeutic use
Male
Memantine - adverse effects - therapeutic use
Nootropic Agents - adverse effects - therapeutic use
Phenylcarbamates - adverse effects - therapeutic use
Piperidines - adverse effects - therapeutic use
Practice Guidelines as Topic
Proportional Hazards Models
Registries
Abstract
The objective of this study was to investigate the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation of AChEI therapy during 2006-2009. We utilized data from a nationwide sample of community-dwelling individuals with a clinically verified Alzheimer's disease diagnosed during the year 2005 (n=6858) as a part of the MEDALZ-2005 study. During the 4-year follow-up, 84% used AChEI and 47% used memantine. Altogether, 22% of the sample used both drugs concomitantly. The median duration of the first AChEI use period was 860 (interquartile range 295-1458) days and 1103 (interquartile range 489-1487) days for the total duration of AChEI use. Although 20% of the AChEI users discontinued the use during the first year, over half of them restarted later. The risk of discontinuation was higher for rivastigmine [hazard ratio 1.34 (confidence interval 1.22-1.48)] and galantamine users [hazard ratio 1.23 (confidence interval 1.15-1.37)] compared with donepezil users in the adjusted model. In conclusion, median time for AChEI use was over 3 years and every fifth Alzheimer's disease patient used AChEI and memantine concomitantly during the follow-up. The low rate of discontinuation is consistent with the Finnish Care Guideline but in contrast to the results reported from many other countries.
Notes
Cites: Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):125-3018525283
Cites: J Am Geriatr Soc. 2007 Oct;55(10):1517-2317697100
Cites: Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):209-2118580597
Cites: J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600-719204022
Cites: Lancet. 2009 Aug 22;374(9690):620-719595447
Cites: Int Psychogeriatr. 2009 Oct;21(5):813-2419538824
Cites: Drugs Aging. 2010 Apr 1;27(4):337-4920359263
Cites: Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):670-920583207
Cites: Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):680-620583209
Cites: CNS Neurosci Ther. 2010 Aug;16(4):235-4520560995
Cites: CNS Drugs. 2010 Sep;24(9):729-3920806986
Cites: Alzheimers Dement. 2011 Mar;7(2):208-4421414557
Cites: Int Clin Psychopharmacol. 2011 Jul;26(4):225-3121394033
Cites: Can J Psychiatry. 2011 Oct;56(10):596-60422014692
Cites: Pharmacoepidemiol Drug Saf. 2012 Sep;21(9):1005-1222718684
Cites: Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1227-3122941581
Cites: BMJ. 1993 Oct 2;307(6908):846-88401129
Cites: J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-4710071091
Cites: CNS Drugs. 2004;18(15):1143-815581384
Cites: Can J Clin Pharmacol. 2004 Fall;11(2):e274-8515604527
Cites: J Manag Care Pharm. 2005 Apr;11(3):231-5115804207
Cites: Drugs Aging. 2005;22(8):695-70716060719
Cites: Alzheimers Dement. 2013 May;9(3):326-3123110864
Cites: Dement Geriatr Cogn Disord. 2013;35(5-6):239-4823485654
Cites: Eur J Clin Pharmacol. 2013 Jul;69(7):1467-7523443628
Cites: Neurology. 2000;54(11 Suppl 5):S10-510854355
Cites: J Am Geriatr Soc. 2003 May;51(5 Suppl Dementia):S289-9512801385
Cites: Clin Ther. 2004 May;26(5):615-3015220008
Cites: Lancet. 2004 Jun 26;363(9427):2105-1515220031
Cites: Am J Geriatr Psychiatry. 2004 Jul-Aug;12(4):358-6915249273
Cites: Expert Opin Drug Saf. 2004 Sep;3(5):425-4015335298
Cites: Neurology. 1984 Jul;34(7):939-446610841
Cites: Cochrane Database Syst Rev. 2006;(1):CD00559316437532
Cites: J Chronic Dis. 1987;40(5):373-833558716
Cites: Eur J Clin Pharmacol. 2007 Nov;63(11):1069-7417712552
Cites: Curr Alzheimer Res. 2008 Feb;5(1):83-918288936
Cites: J Manag Care Pharm. 2008 Jun;14(5):451-6118597574
PubMed ID
24608822 View in PubMed
Less detail

Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort.

https://arctichealth.org/en/permalink/ahliterature166258
Source
Arch Gen Psychiatry. 2006 Dec;63(12):1358-67
Publication Type
Article
Date
Dec-2006
Author
Jari Tiihonen
Jouko Lönnqvist
Kristian Wahlbeck
Timo Klaukka
Antti Tanskanen
Jari Haukka
Author Affiliation
Department of Forensic Psychiatry, University of Kuopio and Niuvanniemi Hospital, Kuopio University Hospital, Kuopio, Finland. Jari.Tiihonen@niuva.fi
Source
Arch Gen Psychiatry. 2006 Dec;63(12):1358-67
Date
Dec-2006
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Antidepressive Agents - adverse effects - therapeutic use
Cause of Death
Child
Cohort Studies
Depressive Disorder - drug therapy - epidemiology - mortality
Female
Finland - epidemiology
Follow-Up Studies
Hospitalization
Humans
Male
Middle Aged
Proportional Hazards Models
Registries
Risk factors
Serotonin Uptake Inhibitors - adverse effects - therapeutic use
Suicide - psychology - statistics & numerical data
Suicide, Attempted - psychology - statistics & numerical data
Abstract
It is unknown if antidepressant treatment is associated with either increased or decreased risk of suicide.
To estimate the risk of suicide, attempted suicide, and overall mortality during antidepressant treatments in a real-life setting with high statistical power.
A cohort study in which all subjects without psychosis, hospitalized because of a suicide attempt from January 1, 1997, to December 31, 2003, in Finland, were followed up through a nationwide computerized database.
A total of 15 390 patients with a mean follow-up of 3.4 years.
The propensity score-adjusted relative risks (RRs) during monotherapy with the most frequently used antidepressants compared with no antidepressant treatment.
In the entire cohort, fluoxetine use was associated with the lowest risk (RR, 0.52; 95% confidence interval [CI], 0.30-0.93), and venlafaxine hydrochloride use with the highest risk (RR, 1.61; 95% CI, 1.01-2.57), of suicide. A substantially lower mortality was observed during selective serotonin reuptake inhibitor use (RR, 0.59; 95% CI, 0.49-0.71; P
Notes
Comment In: Evid Based Ment Health. 2007 Aug;10(3):9017652572
PubMed ID
17146010 View in PubMed
Less detail

Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease.

https://arctichealth.org/en/permalink/ahliterature292637
Source
Int J Geriatr Psychiatry. 2017 12; 32(12):e107-e115
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
12-2017
Author
Sanna Torvinen-Kiiskinen
Anna-Maija Tolppanen
Marjaana Koponen
Antti Tanskanen
Jari Tiihonen
Sirpa Hartikainen
Heidi Taipale
Author Affiliation
Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland.
Source
Int J Geriatr Psychiatry. 2017 12; 32(12):e107-e115
Date
12-2017
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - complications
Antidepressive Agents - therapeutic use
Female
Finland - epidemiology
Hip Fractures - epidemiology
Hospitalization - statistics & numerical data
Humans
Male
Proportional Hazards Models
Retrospective Studies
Risk factors
Abstract
To study whether antidepressant use is associated with an increased risk of hip fracture among community-dwelling persons with and without Alzheimer's disease (AD), and to compare the risk according to duration of use and between antidepressant groups.
Retrospective cohort study, including 50,491 persons with AD (mean age 80) and 100,982 comparison persons without AD from Finnish register-based MEDALZ cohort. Antidepressant use was compared with nonuse with Cox proportional hazard models. Incident users were identified with a one year washout period from Prescription register data. Main outcome was hospitalization due to hip fracture.
During antidepressant use, the age-adjusted rate of hip fractures per 100 person-years was 3.01 (95% CI 2.75-3.34) among persons with and 2.28 (1.94-2.61) among persons without AD. Antidepressant use was associated with an increased risk of hip fracture among persons with and without AD (adjusted HR 1.61, 95% CI 1.45-1.80 and 2.71, 2.35-3.14, respectively) compared with nonuse. The risk was most prominent in the beginning of use and was elevated even up to 4 years. The risk was increased with all of the most frequently used antidepressants.
Antidepressant use is associated with an increased risk of hip fracture among older persons. Copyright © 2017 John Wiley & Sons, Ltd.
Notes
CommentIn: Evid Based Nurs. 2017 Jul;20(3):94 PMID 28601807
PubMed ID
28055139 View in PubMed
Less detail

Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland.

https://arctichealth.org/en/permalink/ahliterature266764
Source
J Clin Psychopharmacol. 2014 Aug;34(4):435-40
Publication Type
Article
Date
Aug-2014
Author
Heidi Taipale
Marjaana Koponen
Antti Tanskanen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Source
J Clin Psychopharmacol. 2014 Aug;34(4):435-40
Date
Aug-2014
Language
English
Publication Type
Article
Keywords
Aged, 80 and over
Alzheimer Disease - drug therapy - epidemiology - psychology
Antipsychotic Agents - administration & dosage
Cohort Studies
Dose-Response Relationship, Drug
Female
Finland - epidemiology
Follow-Up Studies
Humans
Male
Residence Characteristics
Abstract
Use of antipsychotics for treatment of behavioral and psychological symptoms of dementia is frequent among persons with Alzheimer disease (AD). Doses used in long-term therapy have not been previously reported. We describe antipsychotic doses used among community-dwelling persons with AD and investigate factors associated with high-dose use. The MEDALZ-2005 (Medication use and Alzheimer disease) cohort is a nationwide sample including all persons with clinically diagnosed AD at the end of year 2005 in Finland (n = 28,093). Data including prescriptions, comorbidities, and hospital discharge diagnoses were collected from nationwide registers. Antipsychotic doses in monotherapy were investigated during 2006 to 2009. Among 8920 antipsychotic users, 4% (n = 336) used antipsychotics with high dose. Typical antipsychotics were more often used with high dose than atypical antipsychotics. High-dose use was associated with younger age (
PubMed ID
24875073 View in PubMed
Less detail

Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with Alzheimer's disease.

https://arctichealth.org/en/permalink/ahliterature261391
Source
J Alzheimers Dis. 2014;41(4):1223-8
Publication Type
Article
Date
2014
Author
Heidi Taipale
Marjaana Koponen
Antti Tanskanen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Source
J Alzheimers Dis. 2014;41(4):1223-8
Date
2014
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy - epidemiology - psychology
Antipsychotic Agents - therapeutic use
Cohort Studies
Confidence Intervals
Databases, Factual - statistics & numerical data
Female
Finland
Humans
Male
Middle Aged
Polypharmacy
Residence Characteristics
Abstract
Antipsychotic polypharmacy (APP) is not recommended in treatment of behavioral and psychological symptoms of dementia (BPSD). There is lack of studies concerning prevalence of APP among persons with dementia.
The objective of our study was to describe prevalence and risk factors associated with antipsychotic polypharmacy among antipsychotic users with Alzheimer's disease (AD).
Data from nationwide MEDALZ-2005 cohort including all community-dwelling persons diagnosed with AD in Finland was utilized. Register-based data included prescriptions, comorbidities, and hospital discharge diagnoses. Users of antipsychotics during 2006-2009 were included (n = 9,803). The risk of starting antipsychotic polypharmacy was evaluated with Cox proportional hazards model.
Prevalence of antipsychotic polypharmacy was 8% (n = 750) among antipsychotic users (n = 9,803). Quetiapine and risperidone was the most common combination of two antipsychotics followed by combination of quetiapine and haloperidol. Antipsychotic polypharmacy was associated with younger age (HR 1.35 [Confidence Interval, CI, 1.16-1.56]), male gender (HR 1.18 [CI 1.02-1.38]), and history of psychiatric disorder (HR 1.50 [CI 1.26-1.78]) in the adjusted model.
In conclusion, we found higher prevalence of APP than previously reported among older populations. This is concerning since effectiveness of APP has not been demonstrated and APP is not recommended in the treatment of BPSD. Clinicians should pay more attention to avoid APP and use of antipsychotics to other indications than BPSD among persons with AD.
PubMed ID
24787914 View in PubMed
Less detail

Antipsychotic treatment and mortality in schizophrenia.

https://arctichealth.org/en/permalink/ahliterature269903
Source
Schizophr Bull. 2015 May;41(3):656-63
Publication Type
Article
Date
May-2015
Author
Minna Torniainen
Ellenor Mittendorfer-Rutz
Antti Tanskanen
Charlotte Björkenstam
Jaana Suvisaari
Kristina Alexanderson
Jari Tiihonen
Source
Schizophr Bull. 2015 May;41(3):656-63
Date
May-2015
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antipsychotic Agents - adverse effects - pharmacology
Cardiovascular Diseases - chemically induced - mortality
Cohort Studies
Female
Humans
Male
Middle Aged
Registries
Schizophrenia - drug therapy - mortality
Sweden - epidemiology
Young Adult
Abstract
It is generally believed that long-term use of antipsychotics increases mortality and, especially, the risk of cardiovascular death. However, there are no solid data to substantiate this view.
We identified all individuals in Sweden with schizophrenia diagnoses before year 2006 (N = 21 492), aged 17-65 years, and persons with first-episode schizophrenia during the follow-up 2006-2010 (N = 1230). Patient information was prospectively collected through nationwide registers. Total and cause-specific mortalities were calculated as a function of cumulative antipsychotic exposure from January 2006 to December 2010.
Compared with age- and gender-matched controls from the general population (N = 214920), the highest overall mortality was observed among patients with no antipsychotic exposure (hazard ratio [HR] = 6.3, 95% CI: 5.5-7.3), ie, 0.0 defined daily dose (DDD)/day, followed by high exposure (>1.5 DDD/day) group (HR = 5.7, 5.2-6.2), low exposure (
Notes
Cites: Acta Psychiatr Scand Suppl. 2000;401:3-3810887978
Cites: Am J Psychiatry. 2004 Aug;161(8):1334-4915285957
Cites: BMJ. 2006 Jul 1;333(7557):1516790458
Cites: Arch Gen Psychiatry. 2006 Dec;63(12):1358-6717146010
Cites: Fam Pract. 2007 Feb;24(1):34-4017062587
Cites: N Engl J Med. 2009 Jan 15;360(3):225-3519144938
Cites: Scand J Urol Nephrol. 2008;42(4):352-718609293
Cites: Schizophr Res. 2009 Aug;113(1):1-1119524406
Cites: Lancet. 2009 Aug 22;374(9690):620-719595447
Cites: Pharmacogenomics. 2009 Sep;10(9):1511-2619761372
Cites: Am J Psychiatry. 2010 Feb;167(2):151-920008945
Cites: J Clin Psychiatry. 2010 Feb;71(2):103-819895781
Cites: Am J Psychiatry. 2011 Jun;168(6):603-921362741
Cites: Am J Psychiatry. 2013 Mar;170(3):324-3323318474
Cites: Schizophr Bull. 2013 May;39(3):648-5722282455
Cites: PLoS One. 2013;8(6):e6713323826212
Cites: Schizophr Res. 2014 Jan;152(1):246-5424275583
PubMed ID
25422511 View in PubMed
Less detail

67 records – page 1 of 7.